Drugs / Tigulixostat
Tigulixostat
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04966325 | Sep → Dec 2021 | gout | LG Chem | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT06277752 | Mar 2024 | gout | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06189404 | Oct → Nov 2023 | gout | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT04070846 | Feb → Mar 2020 | gout | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT04139824 | Jan → Feb 2020 | gout | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT04066712 | Nov 2019 → Sep 2020 | gout | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT03927677 | Nov 2019 | gout | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT01361646 | Jun 2011 → Jan 2013 | gout | LG Life Sciences | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06501534 | Jul → Dec 2024 | gout | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03934099 | Dec 2019 → May 2021 | gout | LG Chem | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07414394 | Mar 2026 → Apr 2027 expected | gout | Innovent Biologics Technology Limited (Shanghai R&D Center) | Recruiting | No outcome recorded |
| Phase 3 | NCT05586971 | Mar 2023 → May 2025 | gout | LG Chem | Completed | No outcome recorded |
| Phase 3 | NCT05586958 | Oct 2022 → Nov 2024 | gout | LG Chem | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04886050 Comparator | Jul → Sep 2021 | gout | LG Chem | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tigulixostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05586958 ↗ |
| Known as | IBI128 | “Participants in this group receive Tigulixostat (IBI128) tablets together with dummy tablets matching Febuxostat once daily during the 24-week core treatment period, with dose...” NCT07414394 ↗ |
| Known as | LC350189 | “LC350189 200mg qd” NCT04139824 ↗ |
| Action | Inhibit | “Xanthine Oxidase Inhibitor” NCT03934099 ↗ |
| Modality | Small molecule | — CHEMBL3652780 ↗ |
| Route | Oral | “by oral” NCT04066712 ↗ |